• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

信息价值方法是否已准备好进入黄金时代?一项针对非ST段抬高型心肌梗死患者替代治疗策略的应用。

Are value of information methods ready for prime time? An application to alternative treatment strategies for NSTEMI patients.

作者信息

Kent Seamus, Briggs Andrew, Eckermann Simon, Berry Colin

机构信息

Health Economics Research Centre, University of Oxford.

出版信息

Int J Technol Assess Health Care. 2013 Oct;29(4):435-42. doi: 10.1017/S0266462313000433.

DOI:10.1017/S0266462313000433
PMID:24290337
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3846382/
Abstract

OBJECTIVES

The use of value of information methods to inform trial design has been widely advocated but there have been few empirical applications of these methods and there is little evidence they are widely used in decision making. This study considers the usefulness of value of information models in the context of a real clinical decision problem relating to alternative diagnostic strategies for patients with a recent non-ST elevated myocardial infarction.

METHODS

A pretrial economic model is constructed to consider the cost-effectiveness of two competing strategies: coronary angiography alone or in conjunction with fractional flow reserve measurement. A closed-form solution to the expected benefits of information is used with optimal sample size estimated for a range of models reflecting increasingly realistic assumptions and alternative decision contexts.

RESULTS

Fractional flow reserve measurement is expected to be cost-effective with an incremental cost-effectiveness ratio of GBP 1,621, however, there is considerable uncertainty in this estimate and consequently a large expected value to reducing this uncertainty via a trial. The recommended sample size is strongly affected by the reality of the assumptions of the expected value of information (EVI) model and the decision context.

CONCLUSIONS

Value of information models can provide a simple and flexible approach to clinical trial design and are more consistent with the constraints and objectives of the healthcare system than traditional frequentist approaches. However, the variation in sample size estimates demonstrates that it is essential that appropriate model parameters and decision contexts are used in their application.

摘要

目的

信息价值方法在试验设计中的应用已得到广泛倡导,但这些方法的实证应用较少,且几乎没有证据表明它们在决策中得到广泛使用。本研究在与近期非ST段抬高型心肌梗死患者的替代诊断策略相关的实际临床决策问题背景下,考虑信息价值模型的实用性。

方法

构建一个审前经济模型,以考虑两种相互竞争策略的成本效益:单独进行冠状动脉造影或结合血流储备分数测量。信息预期收益的闭式解用于为一系列反映越来越现实假设和替代决策背景的模型估计最优样本量。

结果

血流储备分数测量预计具有成本效益,增量成本效益比为1621英镑,然而,这一估计存在相当大的不确定性,因此通过试验降低这种不确定性具有很大的预期价值。推荐的样本量受到信息预期价值(EVI)模型假设的现实性和决策背景的强烈影响。

结论

信息价值模型可为临床试验设计提供一种简单灵活的方法,并且比传统的频率学派方法更符合医疗保健系统的限制和目标。然而,样本量估计的差异表明,在应用这些模型时,使用适当的模型参数和决策背景至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0698/3846382/dce532d51218/S0266462313000433_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0698/3846382/ff64c7e0afdb/S0266462313000433_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0698/3846382/45b2fe264e4e/S0266462313000433_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0698/3846382/dce532d51218/S0266462313000433_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0698/3846382/ff64c7e0afdb/S0266462313000433_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0698/3846382/45b2fe264e4e/S0266462313000433_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0698/3846382/dce532d51218/S0266462313000433_fig3.jpg

相似文献

1
Are value of information methods ready for prime time? An application to alternative treatment strategies for NSTEMI patients.信息价值方法是否已准备好进入黄金时代?一项针对非ST段抬高型心肌梗死患者替代治疗策略的应用。
Int J Technol Assess Health Care. 2013 Oct;29(4):435-42. doi: 10.1017/S0266462313000433.
2
Non-invasive imaging software to assess the functional significance of coronary stenoses: a systematic review and economic evaluation.评估冠状动脉狭窄功能意义的无创成像软件:系统评价和经济评估。
Health Technol Assess. 2021 Sep;25(56):1-230. doi: 10.3310/hta25560.
3
Cost-Effectiveness of Fractional Flow Reserve-Guided Treatment for Acute Myocardial Infarction and Multivessel Disease: A Prespecified Analysis of the FRAME-AMI Randomized Clinical Trial.血流储备分数指导治疗急性心肌梗死和多血管病变的成本效益:FRAME-AMI 随机临床试验的预设分析。
JAMA Netw Open. 2024 Jan 2;7(1):e2352427. doi: 10.1001/jamanetworkopen.2023.52427.
4
Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.非ST段抬高型急性冠状动脉综合征初始药物治疗替代策略的成本效益:系统评价与决策分析模型
Health Technol Assess. 2005 Jul;9(27):iii-iv, ix-xi, 1-158. doi: 10.3310/hta9270.
5
Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.头孢他啶-阿维巴坦治疗严重需氧革兰氏阴性细菌感染:技术评估以支持新型订阅式支付模式。
Health Technol Assess. 2024 Oct;28(73):1-230. doi: 10.3310/YAPL9347.
6
Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.头孢地尔罗治疗严重需氧革兰氏阴性细菌感染:技术评估以提供一种新的订阅式支付模式。
Health Technol Assess. 2024 Jun;28(28):1-238. doi: 10.3310/YGWR4511.
7
Generalisability in economic evaluation studies in healthcare: a review and case studies.医疗保健经济评估研究中的可推广性:综述与案例研究
Health Technol Assess. 2004 Dec;8(49):iii-iv, 1-192. doi: 10.3310/hta8490.
8
Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial.血流储备分数与血管造影术在指导非ST段抬高型心肌梗死治疗以优化结局中的比较:英国心脏基金会FAMOUS-NSTEMI随机试验
Eur Heart J. 2015 Jan 7;36(2):100-11. doi: 10.1093/eurheartj/ehu338. Epub 2014 Sep 1.
9
A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.心肌梗死后心力衰竭中醛固酮拮抗剂的临床疗效和成本效果的系统评价和经济评估。
Health Technol Assess. 2010 May;14(24):1-162. doi: 10.3310/hta14240.
10
The value of value of information: best informing research design and prioritization using current methods.信息价值的价值:使用现有方法最佳告知研究设计和优先级排序。
Pharmacoeconomics. 2010;28(9):699-709. doi: 10.2165/11537370-000000000-00000.

引用本文的文献

1
Hyperkalemia in chronic kidney disease patients with and without heart failure: an Italian economic modelling study.合并或未合并心力衰竭的慢性肾脏病患者的高钾血症:一项意大利经济模型研究
Cost Eff Resour Alloc. 2024 May 21;22(1):42. doi: 10.1186/s12962-024-00547-y.
2
A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure.在英国进行帕替罗默的成本效益分析:评估心力衰竭和无心力衰竭的慢性肾脏病患者中高钾血症的治疗和终生 RAASi 维持。
BMC Nephrol. 2023 Mar 9;24(1):47. doi: 10.1186/s12882-023-03088-3.
3

本文引用的文献

1
Economic evaluation of fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease.多支血管病变患者中血流储备分数指导的经皮冠状动脉介入治疗的经济学评价。
Circulation. 2010 Dec 14;122(24):2545-50. doi: 10.1161/CIRCULATIONAHA.109.925396. Epub 2010 Nov 29.
2
The value of value of information: best informing research design and prioritization using current methods.信息价值的价值:使用现有方法最佳告知研究设计和优先级排序。
Pharmacoeconomics. 2010;28(9):699-709. doi: 10.2165/11537370-000000000-00000.
3
Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study.
Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD.
达格列净治疗慢性肾脏病的成本效益:DAPA-CKD 的健康经济学分析。
Clin J Am Soc Nephrol. 2022 Dec;17(12):1730-1741. doi: 10.2215/CJN.03790322. Epub 2022 Nov 2.
4
Physiome approach for the analysis of vascular flow reserve in the heart and brain.用于分析心脏和大脑血管血流储备的生理组学方法。
Pflugers Arch. 2017 Jun;469(5-6):613-628. doi: 10.1007/s00424-017-1961-7. Epub 2017 Mar 28.
5
Non-invasive versus invasive management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: study design of the pilot randomised controlled trial and registry (CABG-ACS).既往有冠状动脉旁路移植术的非ST段抬高型急性冠状动脉综合征患者的非侵入性与侵入性治疗:试点随机对照试验和注册研究(CABG-ACS)的研究设计
Open Heart. 2016 Apr 20;3(1):e000371. doi: 10.1136/openhrt-2015-000371. eCollection 2016.
6
Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods.血流储备分数(FFR)与血管造影术在指导非ST段抬高型心肌梗死(FAMOUS-NSTEMI)优化治疗结局管理中的比较:一项探索性试验——采用基于试验和模型的混合方法评估成本效益
Cost Eff Resour Alloc. 2015 Nov 14;13:19. doi: 10.1186/s12962-015-0045-9. eCollection 2015.
7
Sample Size Estimation for Non-Inferiority Trials: Frequentist Approach versus Decision Theory Approach.非劣效性试验的样本量估计:频率学派方法与决策理论方法
PLoS One. 2015 Jun 15;10(6):e0130531. doi: 10.1371/journal.pone.0130531. eCollection 2015.
8
Computing Expected Value of Partial Sample Information from Probabilistic Sensitivity Analysis Using Linear Regression Metamodeling.使用线性回归元建模从概率敏感性分析计算部分样本信息的期望值。
Med Decis Making. 2015 Jul;35(5):584-95. doi: 10.1177/0272989X15578125. Epub 2015 Apr 3.
9
Estimating the Expected Value of Sample Information Using the Probabilistic Sensitivity Analysis Sample: A Fast, Nonparametric Regression-Based Method.使用概率敏感性分析样本估计样本信息的期望值:一种基于快速非参数回归的方法。
Med Decis Making. 2015 Jul;35(5):570-83. doi: 10.1177/0272989X15575286. Epub 2015 Mar 25.
10
Better informing decision making with multiple outcomes cost-effectiveness analysis under uncertainty in cost-disutility space.在成本-效用空间不确定性下,通过多结果成本效益分析更好地为决策提供信息。
PLoS One. 2015 Mar 9;10(3):e0115544. doi: 10.1371/journal.pone.0115544. eCollection 2015.
多支血管病变患者经皮冠状动脉介入治疗中血流储备分数与血管造影的比较:多支血管评估血流储备分数与血管造影(FAME)研究的 2 年随访。
J Am Coll Cardiol. 2010 Jul 13;56(3):177-84. doi: 10.1016/j.jacc.2010.04.012. Epub 2010 May 28.
4
Health technology assessment: lessons learned from around the world--an overview.卫生技术评估:来自世界各地的经验教训——概述
Value Health. 2009 Jun;12 Suppl 2:S1-5. doi: 10.1111/j.1524-4733.2009.00550.x.
5
Optimal clinical trial design using value of information methods with imperfect implementation.利用信息价值方法进行最优临床试验设计,同时考虑不完善的实施情况。
Health Econ. 2010 May;19(5):549-61. doi: 10.1002/hec.1493.
6
Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared.非参数法在成本效益分析中的应用:中心极限定理与自助法的比较。
Health Econ. 2010 Mar;19(3):316-33. doi: 10.1002/hec.1477.
7
Value of information and value of implementation: application of an analytic framework to inform resource allocation decisions in metastatic hormone-refractory prostate cancer.信息价值和实施价值:应用分析框架为转移性激素难治性前列腺癌的资源分配决策提供信息。
Value Health. 2009 Mar-Apr;12(2):315-24. doi: 10.1111/j.1524-4733.2008.00431.x. Epub 2008 Jul 24.
8
Globally optimal trial design for local decision making.用于局部决策的全局最优试验设计。
Health Econ. 2009 Feb;18(2):203-16. doi: 10.1002/hec.1353.
9
Time and expected value of sample information wait for no patient.样本信息的时间和期望值不等人。
Value Health. 2008 May-Jun;11(3):522-6. doi: 10.1111/j.1524-4733.2007.00296.x. Epub 2007 Dec 17.
10
Expected value of information and decision making in HTA.卫生技术评估中的信息期望值与决策制定
Health Econ. 2007 Feb;16(2):195-209. doi: 10.1002/hec.1161.